Especially in view of patients suffering from GBM, spatial tumor dimensions are a well-established independent prognostic factor with respect to overall survival together with other clinicopathological features such as greater extent of resection, younger patient age, better physical condition, and eventually O-6-methylguanine-DNA-methyltransferase promoter methylation status [25, 26]. This evidence concerns the gene MGMT and glioblastoma.